HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia.

Abstract
Endothelial progenitor cells (EPCs) are a subset of the total mononuclear cell population (tMNCs) that possess an enhanced potential for differentiation within the endothelial-cell lineage. Typically, EPCs are selected from tMNCs via the expression of both hematopoietic stem-cell markers and endothelial-cell markers, such as CD34, or by culturing tMNCs in media selective for endothelial cells. Both EPCs and tMNCs participate in vascular growth and regeneration, and their potential use for treatment of myocardial injury or disease has been evaluated in early-phase clinical studies. Direct comparisons between EPCs and tMNCs are rare, but the available evidence appears to favor EPCs, particularly CD34+ cells, and the potency of EPCs may be increased as much as 30-fold through genetic modification. However, these observations must be interpreted with caution because clinical investigations of EPC therapy are ongoing. We anticipate that with continued development, EPC therapy will become a safe and effective treatment option for patients with acute myocardial infarction or chronic ischemic disease.
AuthorsHaruki Sekiguchi, Masaaki Ii, Douglas W Losordo
JournalJournal of cellular physiology (J Cell Physiol) Vol. 219 Issue 2 Pg. 235-42 (May 2009) ISSN: 1097-4652 [Electronic] United States
PMID19115244 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Chemical References
  • Antigens, CD34
  • Biomarkers
Topics
  • Animals
  • Antigens, CD34 (metabolism)
  • Biomarkers (metabolism)
  • Clinical Trials as Topic
  • Endothelial Cells (cytology, physiology)
  • Humans
  • Ischemia (pathology, therapy)
  • Leukocytes, Mononuclear (cytology, physiology)
  • Myocardial Infarction (pathology, therapy)
  • Stem Cell Transplantation
  • Stem Cells (cytology, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: